Finally, because use of a nontargeted TLR7 agonist to treat IPF in humans has been prevented by its systemic activation of the immune system, the question naturally arose whether any obvious toxicities might have accompanied systemic administration of FA‐TLR7‐54 in the mice. This evidence concerns the gene TLR7 and idiopathic pulmonary fibrosis.